Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect Study of HRS-7535 Tablets
NCT06422039Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS-7535 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from Time Zero to Last Quantifiable Concentration and 3 more. Started May 2024; status: completed.
02
Drugs
HRS-7535
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06422039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422039.